Soleil Securities initiates coverage on Valeant Pharmaceuticals Int (NYSE: VRX) with a Sell rating and $14 price target, saying declining ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE